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Background. Subjects with depression and unexplained neurological symptoms have a high prevalence of gastrointestinal
comorbidity probably related to the brain-gut communication. This study explored associations between functional
gastrointestinal disorders (FGID) and inﬂammatory markers in subjects with these disorders. Methods. The FGID, including
irritable bowel syndrome (IBS), were classiﬁed according to the Rome III criteria, and degree of symptoms was assessed with
IBS symptom severity score (IBS-SSS). A range of interleukins (IL), chemokines and growth factors, tryptophan, and kynurenine
were analysed in serum and the cerebrospinal ﬂuid (CSF), and short-chain fatty acids (SCFA) were analysed in the faeces. The
results are reported as partial correlation (pc) and p values. Results. Sixty-six subjects were included. IBS was associated with
high levels of tryptophan (p = 0 048) and kynurenine (p = 0 019) and low level of IL-10 (p = 0 047) in the CSF. IBS-SSS was
associated with high tumor necrosis factor and low IL-10 in the CSF; pc = 0 341 and p = 0 009 and pc = −0 299 and p = 0 023,
respectively. Propionic minus butyric acid in faeces was negatively associated with IL-10 in the CSF (pc = −0 416, p = 0 005).
Conclusions. FGID were associated with a proinﬂammatory immune activation in the central nervous system and a disturbed
tryptophan metabolism that could have been mediated by the faecal microbiota.
1. Background
Comorbidities are common in subjects with depression and
subjects with unexplained somatic symptoms [1, 2]. Func-
tional gastrointestinal disorders (FGID) are particularly com-
mon, probably due to the cross talk between the brain and the
gut through the brain-gut axis [3]. Irritable bowel syndrome
(IBS) is a common functional gastrointestinal disorder
(FGID) with a prevalence rate of approximately 8% in the
Western world [4]. The prevalence rates are signiﬁcantly
higher in subjects with depression and unexplained somatic
disorders [1, 2]. IBS is characterised by abdominal pain and
disturbed bowel functions and a high prevalence of comor-
bidities such as muscle-skeletal pain, fatigue, anxiety, and
depression [5, 6]. The syndrome links the mind and the body
and has been described as a biopsychosocial disorder [7].
This term focuses on the bidirectional relations between the
mind and the body and puts aside the view of diseases as
either somatic or psychological. The cross talk between the
mind and the gut passes through the brain-gut axis that
involves the gut microbiota and the neuronal, neuroendo-
crine, and immunological system [8, 9]. IBS and depression
Hindawi
Gastroenterology Research and Practice
Volume 2017, Article ID 1642912, 9 pages
https://doi.org/10.1155/2017/1642912
have both been associated with immune alterations and fae-
cal dysbiosis [10–13]. The local immune activation seen in
subjects with IBS is modulated by the gut microbiota and
alters the central neural functioning [14]. Faecal dysbiosis
could be a mediator or confounder in the brain-gut commu-
nication. Whether the microbiota per se or the microbiota’s
metabolic activity such as the production of short-chain fatty
acids (SCFA) is involved in the communication is partly
unknown [14]. The communication could be “bottom-up”
(the gut is the cause of the symptoms from the central ner-
vous system) or “top-down” (the central nervous system is
the cause of the gastrointestinal symptoms) depending on
the primary alterations [15].
Depression and FGID have several common pathophysi-
ological abnormalities. Both disorders have been associated
with neural, neuroendocrine, and immune disorders and
deviant tryptophan, serotonin, and kynurenine metabolism
[3, 10, 16–18]. The role of the tryptophan, serotonin, and
kynurenine metabolism has been attributed to be of great
importance [19–21]. Others have focused on the “immune
hypothesis” and studied immunological markers in serum
and the colonic mucosa [10, 16, 22, 23]. Cytokines and neu-
rotrophic factors in the cerebrospinal ﬂuid (CSF) have been
studied in various chronic pain disorders, but not in IBS
[24]. The diﬀerence between IBS andmost of the studied pain
disorders is that the aetiology and pathophysiology of IBS are
unknown. The subjects included in this study had symptoms
related to the central nervous system and a high prevalence of
gastrointestinal comorbidity and were suitable for the study
of the gut-brain interaction.
The aims of this study were to relate the presence of
IBS and the degree of gastrointestinal complaints to the
tryptophan metabolism and inﬂammatory markers in the
blood, the CSF, and faeces in subjects with depression
and unexplained neurological symptoms.
2. Methods
2.1. Study Design. Two groups of subjects, one with depres-
sion and one with unexplained neurological symptoms, were
included in this cross-sectional study. The primary aim of
this study was a secondary aim of a larger project [25]. The
subjects were recruited from the psychiatric and neurological
departments at Innlandet Hospital Trust, Norway. To ascer-
tain the diagnoses of depression and unexplained neurologi-
cal symptoms and exclude other somatic disorders, the
subjects in the depression group were evaluated by a clinical
psychologist and those in the neurological group by a senior
consultant in neurology. The participants ﬁlled in paper-
based questionnaires. A trained study nurse was responsible
for the patient compliance and the practical work. Bio-
markers in the blood, CSF, and faeces were compared in
subjects with and without IBS and associated with the
degree of abdominal complaints.
2.2. Participants. The study included consecutive subjects
above 18 years of age with a diagnosis of idiopathic depres-
sion according to ICD-10, F 32-34 spectre (the depression
group), and subjects with neurological symptoms that
remained unexplained after thorough examinations (the
neurological group). In all subjects, a detailed medical history
and comprehensive clinical, laboratory, and other investiga-
tions were performed according to the doctors’ discretion.
Subjects with drug or alcohol abuse or organic diseases were
excluded. Gender, age (years), previous and present disor-
ders, and use of medicine were noted, and a standard clinical
and neurological examination was performed.
2.3. Variables
2.3.1. Depression. For depression, the following are used:
Beck Depression Inventory-II (BDI-II) (symptoms: mini-
mal, mild, moderate, and severe depression; scores: 0–13,
14–19, 20–28, and 29–63, resp.) and Montgomery-Åsberg
Depression Scale (MADRS) (symptoms: absent, mild,
moderate, and severe depression; scores: 0–6, 7–19, 20–34,
and 35–60, resp.).
2.3.2. Abdominal Complaints. IBS (yes/no) was determined
according to the Rome III criteria. The subjects ﬁlled in a val-
idated Norwegian translation of the Rome III questionnaire
on a paper. A gastroenterologist (the author PGF) performed
the scoring.
IBS symptom severity score (IBS-SSS), which has been
recommended by the Rome Foundation, was used to score
the severity of abdominal complaints [26]. The questionnaire
was, however, responded to by all subjects and not only
subjects with IBS and was used as a measure of the bowel
symptom severity independent of the presence of IBS. The
score ranges from 0 to 500.
2.3.3. Blood Tests. The blood samples were collected in the
morning before 10 a.m., were allowed to clot for 30 minutes,
were centrifuged for 10 minutes at 2000g, and were stored
at −70°C before being analysed. The subjects were not
asked to be fasting.
Twenty-seven interleukins (IL), chemokines, and growth
factors were analysed in serum: IL-1β; IL-1 receptor antago-
nist (IL-1Ra); IL-2; IL-4; IL-5; IL-6; IL-7; IL-8 (CXCL8); IL-9;
IL-10; IL-12 (p70); IL-13; IL-15; IL-17; eotaxin/CCL11; basic
ﬁbroblast growth factor; granulocyte-colony stimulating
factor (G-CSF); granulocyte macrophage CSF; interferon-
(IFN-) γ; IFN-inducible protein 10 (IP-10; CXCL10);
monocyte chemoattractant protein 1 (MCP-1; CCL2);
macrophage inﬂammatory peptide- (MIP-) 1α (CCL3);
MIP-1β (CCL4); platelet-derived growth factor-BB; regu-
lated on activation, normal T-cell expressed and secreted
(RANTES; CCL5) tumor necrosis factor (TNF); and vascular
endothelial growth factor. The samples were analysed on a
Multiplex Analyzer using a multiplex cytokine assay (Bio-
Plex Human Cytokine 27-Plex Panel; Bio-Rad Laboratories
Inc., Hercules, CA, USA). The TNF/IL-10 ratio was calcu-
lated because the results indicated an inverse correlation.
Tryptophan, kynurenine, and kynurenine/tryptophan
ratio× 1000 (K/T ratio× 1000) were measured in serum. Free
tryptophan and kynurenine were extracted by the addition of
trichloroacetic acid followed by centrifugation. The superna-
tant was then analysed using gradient elution and quantiﬁed
by ultraviolet (UV) for kynurenine and tryptophan. The LC
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system was of type Inﬁnity 1290 (Agilent Technologies Inc.,
Palo Alto, CA, USA) applying a reversed phase Kinetex,
2.6μ C18 100A UPLC column (Phenomenex). The mea-
surements were performed by Vitas AS, Oslo, Norway
(tryptophan: range 10–100μM; kynurenine: range 0.8–5μM;
detection limit for both: 0.1μM).
2.3.4. Cerebrospinal Fluid (CFS). Spinal puncture was per-
formed on nonfasting subjects before 12 a.m., except for
two subjects who had the puncture at 1 p.m. The spinal
ﬂuid was immediately stored at −70°C.
Twenty-four ILs, chemokines, and growth factors (the
same ones as in serum except for IL-7, IL-12, and G-CSF that
were not detectable in the CSF) and tryptophan, kynurenine,
and K/T ratio× 1000 were analysed in the CSF.
2.3.5. Faecal Samples. Stool collected at home was immedi-
ately frozen at −20°C and later transported to the hospital
in the frozen state. The stool collected at the hospital and
the stool transported to the hospital at −20°C were immedi-
ately brought to a freezer with −70°C. Within one month,
S.T.A.R. (Stool Transport and Recovery; Roche, Basel,
Switzerland) buﬀer solution was added to the samples
(stool/S.T.A.R. ratio 1/3) and vortexed to a homogenous
suspension and stored at −80°C.
Stool samples were analysed for short-chain fatty acids
(acetic acid, propionic acid, butyric acid, isobutyric acid,
valeric acid, and isovaleric acid) by gas chromatography.
The Thermo Focus with a ﬂame ionization detector (Thermo
Fisher, Waltham, Massachusetts, USA) was used. Helium
was used as carrier gas, and the column used was 30m-long
Stabilwax-DA from Restek with polyethylene glycol (PEG)
as the stationary phase. The chromatography conditions
were as follows: gas pressure 0.6 bar; injector temperature
210°C; start temperature 80°C; temperature program 0°C/
min for 3min, 23.3°C/min for 3min, and 25°C/min for
2min; end temperature 200°C; and detector temperature
230°C [27]. In addition to the individual fatty acids, the dif-
ference between propionic and butyric acids (PmB), which
has been shown to be a potential biomarker for IBS, was used
in the analyses [28].
2.3.6. Supplementary Investigations. In the neurological
group, computer tomography or magnetic resonance
Table 1: Characteristics of the participants in the two groups with comparisons between the groups.
Variables (number of subjects in the analyses if less than 66)
Neurological group
n = 19
Depression group
n = 47
Statistics
p value
Female 12/19 (63%) 25/47 (53%) 0.586∗
Age (years) 47 (14) 45 (14) 0.506
BDI-II 6.5 (6.7) 30.4 (12.6) <0.001
IBS 6/19 (32%) 27/47 (57%) 0.102∗
IBS-SSS (n = 65) 113 (88) 200 (103) 0.003
INF-γ serum (pg/ml) 63.1 (29.2; 83.0) 54.7 (29.2; 86.4) 0.025∗∗
IL-1ra serum (pg/ml) 180 (117; 268) 161 (94; 1825) 0.027∗∗
IL-10 serum (pg/ml) 4.05 (2.10; 8.55) 2.99 (0.69; 12.72) 0.040∗∗
TNF serum (pg/ml) 30.9 (4.5) 29.8 (5.5) 0.459
TNF/IL-10 ratio serum 7.24 (3.80; 16.19) 9.77 (2.99; 31.88) 0.029∗∗
Exotaxin-CSF (pg/ml) (n = 62) 2.30 (0.99; 27.79) 1.44 (0.53; 57.73) 0.042∗∗
IL-10-CSF (pg/ml) (n = 62) 1.64 (0.36) 1.53 (0.32) 0.251
TNF-CSF (pg/ml) (n = 62) 1.60 (0.96) 1.43 (0.80) 0.470
TNF/IL-10 ratio CSF (n = 62) 1.0 (0.7) 1.0 (0.5) 0.731
Kynurenine serum (μM) (n = 62) 2.00 (0.58) 2.17 (0.53) 0.286
Tryptophan serum (μM) (n = 62) 56.5 (11.1) 58.1 (12.4) 0.640
K/T ratio× 1000 serum (n = 62) 36.1 (9.7) 38.2 (10.1) 0.447
Kynurenine CSF (μM) (n = 62) 0.055 (0.037; 0.097) 0.057 (0.032; 0.148) 0.572∗∗
Tryptophan CSF (μM) (n = 62) 2.12 (1.56; 6.23) 2.07 (1.36; 144.50) 0.708∗∗
K/T ratio× 1000 CSF (n = 62) 26.4 (7.0) 27.1 (12.2) 0.823
Propionic acid faeces (mmol/l) (n = 50) 1.77 (1.11) 1.57 (1.33) 0.582
Butyric acid faeces (mmol/l) (n = 50) 2.02 (1.63) 1.40 (1.24) 0.142
PmB in faeces (mmol/l) (n = 50) −0.25 (0.76) 0.16 (0.53) 0.031
The results are given as number and proportion (%), mean with standard deviation, and median with range. Fisher’s exact test (marked with ∗ ), t-test, and
Mann–Whitney U test (∗∗ ) were used for the comparisons between the groups. BDI-II: Beck Depression Inventory-II; IBS: irritable bowel syndrome; IBS-
SSS: irritable bowel syndrome symptom severity score; INF-γ serum: interferon gamma in serum; IL-10-CSF: interleukin 10 in the cerebrospinal ﬂuid; TNF
serum and TNF-CSF: tumor necrosis factor in serum and tumor necrosis factor in the cerebrospinal ﬂuid; PmB: propionic acid minus butyric acid; K/T
ratio × 1000: kynurenine/tryptophan ratio × 1000.
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imaging was performed in all subjects. Otherwise, supple-
mentary examinations were carried out at the doctors’ discre-
tion in both groups.
2.4. Statistics. The subjects’ characteristics have been
reported separately for the neurological and depression
groups with comparisons between the groups. All the subse-
quent regression analyses were adjusted for the groups
(depression versus neurological) and the degree of depres-
sion, which was found to be a confounder. Since BDI-II
was a stronger predictor of IBS and IBS-SSS than MADRS,
and BDI-II and MADRS were highly correlated, only
BDI-II was used in the analyses. Logistic regression analy-
ses with IBS as the dependent variable and linear regres-
sion with IBS-SSS as the dependent variable were carried
out with one by one of all the other variables (clinical data,
questionnaires, blood tests, analyses of the CSF, and faecal
samples) as covariates. From these analyses, we report all
the statistically signiﬁcant covariates as well as the covari-
ates judged as relevant. Variables associated with IBS and
IBS-SSS in the ﬁrst set of analyses were together with the
group and depression included in further logistic and
linear regression analyses. The analyses have been checked
for collinearity, and the residuals have been checked for
normality and outliers. IBM SPSS Statistics for Windows,
version 22.0. Armonk, NY, IBM Corp., was used for most
of the analyses. Fractional polynomial modeling with
STATA Release 13, StataCorp LP, Texas, USA, was used
for the multivariable analyses where a linear function of
the covariate was unﬁt. p values < 0.05 were judged as
statistically signiﬁcant.
2.5. Ethics. The study was approved by the Norwegian
Regional Committees for Medical and Health Research
Ethics, PB 1130, Blindern, 0318 Oslo, Norway (reference
number 2009/2196a) and performed in accordance with the
Declaration of Helsinki. Written informed consent was given
by all participants before inclusion.
3. Results
Out of 21 and 49 subjects included in the depression and
neurological groups of the main project, 19 and 47, respec-
tively, had serum samples for the analyses of inﬂammatory
markers and satisfactorily ﬁlled in questionnaires for the
scoring of IBS and were included in this study. Analysis of
IBS-SSS was missing in one patient in the neurological group,
analyses of the CSF were missing in four subjects in the
depression group, and analyses of faeces were missing in
two subjects in the neurological group and 14 in the depres-
sion group. In the neurological group, fatigue, headache,
muscle or other pain syndromes, dizziness, and ataxia were
the most commonly reported unexplained symptoms.
Table 1 gives the subjects’ characteristics in the two groups
with comparisons between the groups.
Table 2: Predictors of IBS. The covariates in the analyses were the groups (neurological/depression), depression (BDI-II), and one by one of
the other variables.
Group BDI-II Other variables
OR (95% CI) p value OR (95% CI) p value OR (95% CI) p value
2.93 (0.95; 9.03) 0.062
0.66 (0.13; 3.31) 0.617 1.07 (1.02; 1.12) 0.012
0.58 (0.11; 3.00) 0.511 1.07 (1.02; 1.13) 0.009 Gender (male) 1.71 (0.58;5.09) 0.333
0.64 (0.13; 3.24) 0.590 1.07 (1.02; 1.13) 0.011 Age (years) 1.00 (0.97;1.05) 0.723
0.69 (0.14; 3.46) 0.651 1.07 (1.02; 1.13) 0.009 IL-10 serum (pg/ml) 1.12 (0.88;1.43) 0.357
0.75 (0.15; 3.79) 0.725 1.07 (1.02; 1.12) 0.013 TNF serum (pg/ml) 1.07 (0.95; 1.20) 0.246
0.73 (0.14; 3.72) 0.702 1.07 (1.02; 1.12) 0.011 TNF/IL-10 ratio serum 0.97 (0.87; 1.08) 0.572
0.59 (0.10; 3.46) 0.561 1.07 (1.01; 1.13) 0.020 IL-10-CSF (pg/ml) 0.15 (0.02; 0.97) 0.047
0.56 (0.10; 3.11) 0.509 1.08 (1.02; 1.13) 0.008 TNF-CSF (pg/ml) 1.10 (0.57; 2.11) 0.776
0.59 (0.11; 3.33) 0.550 1.07 (1.02; 1.13) 0.011 TNF/IL-10 ratio CSF 1.34 (0.52; 3.48) 0.548
0.49 (0.09; 2.76) 0.418 1.08 (1.02; 1.14) 0.007 Kynurenine serum 1.52 (0.54; 4.30) 0.429
0.46 (0.08; 2.61) 0.384 1.08 (1.02; 1.15) 0.005 Tryptophan serum 1.05 (0.99; 1.11) 0.107
0.56 (0.10; 3.05) 0.500 1.08 (1.02; 1.14) 0.008 K/T× 1000 serum 0.99 (0.94; 1.05) 0.754
0.55 (0.10; 2.97) 0.482 1.08 (1.02; 1.14) 0.008 Kynurenine CSF >1.00 0.019∗
0.53 (0.09; 3.19) 0.489 1.08 (1.02; 1.14) 0.009 Tryptophan CSF >1.00 0.048∗
0.54 (0.10; 2.96) 0.480 1.08 (1.02; 1.14) 0.008 K/T× 1000 CSF 1.00 (0.95; 1.05) 0.844
0.32 (0.04; 2.29) 0.254 1.13 (1.04; 1.22) 0.004 Propionic acid faeces 1.90 (1.04; 3.46) 0.036
0.35 (0.05; 2.34) 0.280 1.11 (1.03; 1.20) 0.007 Butyric acid faeces 1.06 (0.67; 1.69) 0.800
0.08 (0.01; 1.10) 0.059 1.17 (1.05; 1.31) 0.006 PmB faeces 6992 (10; 4,793,010) 0.008
∗Fractional polynomial logistic regression. BDI-II: Beck Depression Inventory-II; IL-10 serum: interleukin 10 in the serum; TNF serum: tumor necrosis factor
in serum; IL-10-CSF: interleukin 10 in the cerebrospinal ﬂuid; TNF-CSF: tumor necrosis factor in the cerebrospinal ﬂuid; PmB: propionic acid minus butyric
acid in faeces; K/T ratio × 1000: kynurenine/tryptophan ratio × 1000.
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Table 2 gives the predictors of IBS adjusted for the group
and depression (BDI-II). Low values of IL-10 and high values
of kynurenine and tryptophan in the CSF and high levels of
propionic acid and PmB in faeces were signiﬁcant predictors
of IBS.
Table 3 gives the predictors of IBS-SSS adjusted for the
group and depression (BDI-II). High level of TNF and a high
TNF/IL-10 ratio in the CSF were predictors of IBS-SSS.
Table 4 gives the predictors of IBS and IBS-SSS adjusted
for the group, BDI-II, TNF, and IL-10 in serum and CSF.
Figure 1 presents the associations between IBS-SSS and
high TNF and low IL-10-CSF values, which were the main
ﬁndings. PmB was negatively associated with IL-10-CSF
after adjusting for the group, BDI-II, and TNF-CSF (B:
−0.86; 95% CI: −1.44 to −0.27; p = 0 005; pc = −0 416).
None of the markers in serum was associated with either
IBS or IBS-SSS.
4. Discussion
4.1. General Discussion. The study conﬁrmed the high preva-
lence of gastrointestinal comorbidity in subjects with depres-
sion and unexplained neurological symptoms and showed
signiﬁcant correlations between FGID and neuroimmune
activation and disturbed tryptophan metabolism in the cen-
tral nervous system. IBS and IBS-SSS were associated with
low levels of the anti-inﬂammatory cytokine IL-10 in the
CSF. In addition, IBS-SSS was associated with high levels of
the proinﬂammatory cytokine TNF. The severity of abdomi-
nal pain or discomfort (IBS-SSS) and not the cause of the
symptoms (IBS) was the main predictor of the proinﬂamma-
tory response seen in the CSF. It is known that pain, includ-
ing gastrointestinal pain, involves peripheral neuroimmune
reactions, but central neuroimmune reactions have been less
well studied. In a published review, Bjurstrom et al. wrote
that “In various preclinical chronic pain models, cytokines
and neurotrophic factors have been identiﬁed as pivotal medi-
ators involved in neuroimmune activation pathways and cas-
cades, and in neuron-glia interactions. Research conﬁrming
these ﬁndings in humans has so far been scarce and never eval-
uated in a comprehensive manner” [24]. This study supports
the preclinical data in a clinical study.
TNF is a pronociceptive cytokine thought to sensitise
neurons and stimulate the release of other proinﬂammatory
cytokines such as IL-1β and IL6. IL-10 is an anti-
inﬂammatory cytokine acting by inhibition of nuclear factor
kappa B and suppressing the production of proinﬂammatory
cytokines including TNF [24]. An increase in TNF and
decrease in IL-10 may reﬂect a net proinﬂammatory eﬀect
in the central nervous system. The associations between the
cytokines and IBS-SSS were stronger and more convincing
than the associations with IBS, indicating that TNF and IL-
10 are better biomarkers of perceived severity of FGID than
the presence of IBS.
The composition and function of the faecal microbiota
are essential for the immune system and are crucial for the
Table 3: Predictors of IBS-SSS. The covariates in the analyses were the groups (neurological/depression), depression (BDI-II), and one by one
of the other variables.
Group BDI-II Other variables
B (95% CI) p value B (95% CI) p value B (95% CI) p value
86 (31; 141) 0.003
28 (−45; 102) 0.444 2.4 (0.3; 4.6) 0.027
23 (−51; 98) 0.533 2.6 (0.4; 4.7) 0.021 Gender (male) 24 (−24; 73) 0.317
23 (−51; 98) 0.529 2.8 (0.6; 5.0) 0.015 Age (years) 1.0 (−0.7; 2.8) 0.252
28 (−46; 102) 0.454 2.4 (0.2; 4.6) 0.031 IL-10 serum (pg/ml) −1.5 (−12.6; 9.6) 0.787
30 (−45; 105) 0.429 2.4 (0.3; 4.6) 0.029 TNF serum (pg/ml) 0.8 (−3.9; 5.4) 0.745
24 (−51; 99) 0.526 2.4 (0.3; 4.6) 0.028 TNF/IL-10 ratio serum 1.8 (−3.2; 6.8) 0.480
23 (−54; 99) 0.551 2.3 (0.0; 4.5) 0.048 IL-10-CSF (pg/ml) −69 (−146; 9) 0.084
30 (−46; 106) 0.432 2.5 (0.3; 4.7) 0.024 TNF-CSF (pg/ml) 32 (3; 61) 0.030
33 (−42; 108) 0.380 2.2 (0.0; 4.4) 0.046 TNF/IL-10 ratio CSF 55 (13; 97) 0.012
21 (−58; 101) 0.595 2.7 (0.5; 2.0) 0.020 Kynurenine serum 0.5 (−46.2; 47.1) 0.984
24 (−53; 102) 0.530 2.6 (0.4; 4.9) 0.021 Tryptophan serum −1.4 (−3.5; 0.7) 0.194
17 (−61; 95) 0.668 2.8 (0.5; 5.0) 0.017 K/T× 1000 serum 1.3 (−1.2; 3.8) 0.304
34 (−44; 111) 0.387 2.4 (0.2; 4.6) 0.034 Kynurenine CSF (pg/ml) >1 0.062∗
22 (−56; 100) 0.577 2.8 (0.6; 5.0) 0.015 Tryptophan CSF (pg/ml) >1 0.150∗
21 (−57; 99) 0.589 2.7 (0.5; 5.0) 0.019 K/T× 1000 CSF −0.3 (−2.6; 2.0) 0.797
40 (−42; 122) 0.332 2.6 (−0.2; 5.3) 0.065 Propionic acid faeces (mmol/l) 1.9 (−20.7; 24.4) 0.869
35 (−47; 118) 0.390 2.5 (−0.2; 5.2) 0.070 Butyric acid faeces (mmol/l) −7.2 (−27.7; 13.2) 0.481
22 (−58; 102) 0.580 2.4 (−0.1; 5.1) 0.063 PmB faeces (mmol/l) 44 (−0.4; 87.6) 0.052
∗Fractional polynomial linear regression. BDI-II: Beck Depression Inventory-II; IL-10 serum: interleukin 10 in the serum; TNF serum: tumor necrosis factor in
serum; IL-10-CSF: interleukin 10 in the cerebrospinal ﬂuid; TNF-CSF: tumor necrosis factor in the cerebrospinal ﬂuid; PmB: propionic acid minus butyric acid
in faeces; K/T ratio × 1000: kynurenine/tryptophan ratio × 1000.
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brain-gut communication [14]. Faecal SCFA, which are
produced by the microbiota through fermentation of indi-
gestible polysaccharides and proteins, inﬂuence gastroin-
testinal motility, the gastrointestinal immune system,
metabolism, and cell proliferation [29, 30]. In contrast to
a comprehensive literature on the peripheral eﬀects of
the microbiota and SCFA, little is known about the central
nervous eﬀects of SCFA. In this study, propionic acid and
PmB were signiﬁcantly associated with IBS, and PmB was
negatively associated with IL-10 in the CSF, which may
suggest that the SCFA are involved in the brain-gut com-
munication. The SCFA were not signiﬁcantly associated
with the symptom severity. The discrepancy between IBS
and perceived symptom severity could indicate that the
pathophysiology of IBS diﬀers from that of the perceived
severity of the FGID.
Advanced neuroimaging techniques have demonstrated
the cerebral involvement in IBS [17, 31, 32]. These ﬁndings
have not been related to central immunological markers. Pre-
clinical studies implicate that proinﬂammatory peripheral
and central cytokines induce and maintain chronic pain
states by central sensitisation [24, 33, 34]. FGID diﬀer from
other pain syndromes and preclinical studies by the absence
of known aetiology. The central neuroimmune activation
shown in this study might be associated with a central sensi-
tisation that contributes to the chronicity of the disorder by
an exaggerated and long-lasting response to normal and
abnormal stimuli.
In subjects with IBS, a cytokine imbalance in serum and
the gastrointestinal mucosa has been shown in several studies
[22, 23, 35]. Reviews have demonstrated an imbalance of pro-
inﬂammatory TNF and anti-inﬂammatory IL-10 in serum/
plasma of subjects with IBS. [23, 36]. This study could not
conﬁrm the results, but the same cytokines in the CSF were
associated with symptom severity. In most studies, immune
markers have been compared in subjects with and without
IBS without taking into account the severity of the disor-
ders. Liebregts et al. showed a signiﬁcant association
between elevated TNF and IL6 in the blood and the sever-
ity of both gastrointestinal symptoms and anxiety [37].
Not having taken into account the severity of the disorder
could explain the discrepancies between studies of the
immune imbalance in FGID.
The tryptophan-kynurenine metabolism has been asso-
ciated with a broad range of diseases in the central nervous
system, including depression [21, 38]. The tryptophan-
kynurenine metabolism is regulated by inﬂammatory cyto-
kines, and the metabolites are therefore also inﬂammatory
markers. The enzyme indole-2,3-dioxygenase (IDO), which
is central in the metabolism of tryptophan, is regulated
mainly by INF-γ and also by IL-10 and TNF [38]. It is
likely that the high tryptophan and kynurenine values that
were seen in the CSF in subjects with IBS were associated
with the central immune activation. The tryptophan-
serotonin-kynurenine pathway has been attributed to be
of great importance for the pathophysiology of IBS [19,
20, 39]. A high K/T ratio due to increased catabolism of
tryptophan through the kynurenine pathway is a marker
of inﬂammation and has been associated with IBS severity
and proposed as a biomarker for IBS [39, 40]. This study
did not support these ﬁndings.
The associations between the central immune activation,
neuroimaging, and disorders such as depression, gastrointes-
tinal complaints, anxiety, fatigue, and muscle-skeletal pain
deserve further investigations. It is unknown if any of
today’s treatments for either depression or FGID, be it
drugs, psychotherapy or cognitive therapy, have a central
immune-modulating eﬀect. In the future, therapy aiming at
the reduction of the central immune activation might be
an alternative for a subgroup of subjects with severe gastro-
intestinal comorbidity.
4.2. Strengths and Limitations. The study was designed to
compare immune markers including tryptophan and
kynurenine in subjects with depression and unexplained
neurological symptoms. These subjects have a high preva-
lence of comorbidity including FGID, which makes them
suitable for the study of FGID. The groups were well bal-
anced except for the degree of depression. The limitation
related to the inclusion of two diﬀerent groups of subjects
was minimised by adjusting the analyses for the groups
and degree of depression.
The inclusion of a healthy control group or a group
with isolated FGID would have strengthened the study
design. However, to perform a spinal puncture to collect
the CSF in healthy volunteers was judged as unethical
and would probably not have been approved by the
ethics committee.
Despite the limited number of participants, the main
results were convincing and highly statistically signiﬁcant.
The high number of variables used in the analyses of
associations with IBS and IBS-SSS without correcting for
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Figure 1: The ﬁgure shows the associations between TNF and IL-10
in the cerebrospinal ﬂuid (CSF) and perceived symptom severity
(IBS symptom severity score) measured at the average of the other
covariates.
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multiple analyses has increased the probability of type I
errors. It strengthens the credibility of the results that the
inﬂammatory markers most often mentioned in relation to
IBS (TNF and IL-10) were the only statistically signiﬁcant
inﬂammatory predictors in this study.
5. Conclusions
In this study, high TNF and low IL-10 levels in the CSF
were associated with the perceived severity of FGID, and
high levels of tryptophan and kynurenine and low levels
of IL-10 in the CSF were associated with IBS. The ﬁndings
might indicate that the gastrointestinal complaints are
associated with a proinﬂammatory central immune activa-
tion and an abnormal tryptophan metabolism which could
cause and maintain the chronicity of the disorder by a central
and long-lasting sensitisation that exaggerates normal and
abnormal visceral stimuli.
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